Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure

Heart and Vessels

Volumn 27, Issue 6, 2012, Pages 568-575

  Kozdaǧ, Güliz ^a   Yaymaci, Mehmet ^a   Ertaş, Gökhan ^b   Çelikyurt, Umut ^a   Şahin, Tayfun ^a   Kiliç, Teoman ^a   Ural, Dilek ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b Gümü hane Government Hospital   (Turkey)

Author keywords

Aspirin; Chronic heart failure; Clopidogrel; Mortality; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ADULT; ARTICLE; CAUSE OF DEATH; CHRONIC DECOMPENSATED HEART FAILURE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG USE; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; AGED; CHI SQUARE DISTRIBUTION; CHRONIC DISEASE; CLINICAL PRACTICE; COMPARATIVE STUDY; DRUG INTERACTION; DRUG UTILIZATION; HEALTH CARE SURVEY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS; TIME; TURKEY (REPUBLIC);

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ASPIRIN; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DRUG INTERACTIONS; DRUG UTILIZATION; FEMALE; HEALTH CARE SURVEYS; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PATIENT READMISSION; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; TICLOPIDINE; TIME FACTORS; TURKEY; VENTRICULAR FUNCTION, LEFT; WARFARIN;

EID: 84876570602     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-011-0185-6     Document Type: Article

References (47)

1. Sytkowski PA, Kannel WB, D'Agostino RB (1990) Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 322:1635-1641
2. Ghali JK, Cooper R, Ford E (1990) Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence. Arch Intern Med 150:769-773
3. Gheorghiade M, Bonow RO (1998) Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97:282-289
4. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD, Resource Utilization Among Congestive Heart Failure (REACH) Study (2002) Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 39:60-69
5. Felker GM, Shaw LK, O'Connor CM (2002) A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 39:210-218
6. Miller LW, Missov ED (2001) Epidemiology of heart failure. Cardiol Clin 19:547-555
7. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M (2006) The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113:1424-1433
8. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ (2002) The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 4:361-371
9. O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC (2008) Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 156:662-673
10. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG (1994) Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 127:607-612
11. Gibbs CR, Blann AD, Watson RD, Lip GY (2001) Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 103:1746-1751
12. Nixon JV (1983) Left ventricular mural thrombus. Arch Intern Med 143:1567-1571
13. Efremidis M, Pappas L, Sideris A, Filippatos G (2008) Management of atrial fibrillation in patients with heart failure. J Card Fail 14:232-237
14. Cleland JG (1997) Anticoagulant antiplatelet therapy in heart failure. Curr Opin Cardiol 12:276-287
15. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moyé LA, Goldhaber SZ, Pfeffer MA (1997) Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 336:251-257
16. Lip GY, Gibbs CR (1999) Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 33:1424-1426
17. Lip GY, Gibbs CR (2002) Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. QJM 95:461-468
18. Subramaniam V, Davis RC, Shantsila E, Lip GY (2009) Antithrombotic therapy for heart failure in sinus rhythm. Fundam Clin Pharmacol 23:705-717
19. Mehta J, Mehta P, Platelet function studies in heart disease (1979) Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside. Circulation 60:497-503
20. Andreassen AK, Nordøy I, Simonsen S, Ueland T, Müller F, Frøland SS, Gullestad L, Aukrust P (1998) Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol 81:604-608
21. Devaux B, Scholz D, Hirche A, Klövekorn WP, Schaper J (1997) Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 18:470-479
22. Elkayam U, Cohen G, Gogia H, Mehra A, Johnson JV, Chandraratna PA (1996) Renal vasodilatory effect of endothelial stimulation in patients with chronic congestive heart failure. J Am Coll Cardiol 28:176-182
23. Levine TB, Levine AB (1990) Regional blood flow supply, demand in heart failure. Am Heart J 120:1547-1551
24. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR, WATCH Trial Investigators (2009) Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 119:1616-1624
25. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA (2004) The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 148:157-164
26. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA (1998) Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 31:419-425
27. Jhund PS, Davie AP, McMurray JJ (2001) Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. J Am Coll Cardiol 37:1234-1238
28. Savi P, Labouret C, Delesque N, Guette F, Lupker J, Herbert JM (2001) P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 283:379-383
29. Herbert JM, Bernat A, Maffrand JP (1993) Aprotinin reduces clopidogrel-induced prolongation of the bleeding time in the rat. Thromb Res 71:433-441
30. Herbert JM, Tissinier A, Defreyn G, Maffrand JP (1993) Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb 13:1171-1179
31. Herbert JM, Bernat A, Maffrand JP (1992) Importance of platelets in experimental venous thrombosis in the rat. Blood 80:2281-2286
32. Yao SK, Ober JC, Ferguson JJ, Maffrand JP, Anderson HV, Buja LM, Willerson JT (1994) Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 267:488-493
33. Awidi A, Saleh A, Dweik M, Kailani B, Abu-Fara M, Nabulsi R, Bener A (2010) Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study. Heart Vessels. doi: 10.1007/s00380-010-0086-0
34. Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, Tanguay JF, Steinhubl SR, O'Connor CM (2003) Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 146:713-720
35. Subramaniam V, Davis RC, Shantsila E, Lip GY (2009) Antithrombotic therapy for heart failure in sinus rhythm. Fundam Clin Pharmacol 23:705-717
36. Nguyen KN, Aursnes I, Kjekshus J (1997) Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 79:115-119
37. Malinin AI, O'Connor CM, Dzhanashvili AI, Sane DC, Serebruany VL (2003) Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? Am Heart J 145:397-403
38. Peterson JG, Topol EJ, Sapp SK, Young JB, Lincoff AM, Lauer MS (2000) Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med 109:371-377
39. Leor J, Reicher-Reiss H, Goldbourt U, Boyko V, Gottlieb S, Battler A, Behar S (1999) Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 33:1920-1925
40. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S (2006) Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368:581-588
41. Blais C Jr, Drapeau G, Raymond P, Lamontagne D, Gervais N, Venneman I, Adam A (1997) Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am J Physiol 273:2263-2271
42. Heesch CM, Crandall ME, Turbek JA (1996) Converting enzyme inhibitors cause pressure-independent resetting of baroreflex control of sympathetic outflow. Am J Physiol 270:728-737
43. Juhlin T, Jönsson BA, Höglund P (2008) Renal effects of aspirin are clearly dose-dependent and are of clinical importance from a dose of 160 mg. Eur J Heart Fail 10:892-898
44. Meune C, Mahé I, Solal AC, Lévy BI, Duboc D, Simoneau G, Champion K, Mourad JJ, Weber S, Bergmann JF (2006) Comparative effect of aspirin and clopidogrel on arterial function in CHF. Int J Cardiol 106:61-66
45. Kindsvater S, Leclerc K, Ward J (2003) Effects of coadministration of aspirin or clopidogrel on exercise testing in patients with heart failure receiving angiotensin-converting enzyme inhibitors. Am J Cardiol 91:1350-1352
46. Meune C, Wahbi K, Fulla Y, Cohen-Solal A, Duboc D, Mahé I, Simoneau G, Bergmann JF, Weber S, Mouly S (2007) Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors. Eur J Heart Fail 9:197-201
47. Furuno T, Yamasaki F, Yokoyama T, Sato K, Sato T, Doi Y, Sugiura T (2011) Effects of various doses of aspirin on platelet activity and endothelial function. Heart Vessels 26:267-273